5 курс / Пульмонология и фтизиатрия / Ведение пожилого больного ХОБЛ

02_Rak_of_old_people_4.qxd 01.12.2005 19:25 Page 211

33.Ducolone A., Vandevenne A., Jouin H., et al. Gastroesophageal reflux in patients with asthma and chronic bronchitis. Am Rev. Respir. Dis. 1987; 135: 327—332.

34.Dusser D., Bravo M., Iacono P., et al. On Behalf of the Mistral Study Group. Tiotropium reduces COPD exacerbations: the MISTRAL study (abstract 3203). Eur. Respir. J. 2004; 24 (Suppl. 48): 513 s.

35.Ebeling P., Erbas B., Hopper J., et al. Bone mineral density and bone turnover in asthmatics treated with long term inhaled or oral glucocorticoids. J. Bone Miner. Res. 1998; 12: 1283—1289.

36.Eller J., Ede A., Schaberg T., et al. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542—1548.

37.El Serag H.B., Sonnenberg A. Comorbid occurrence of laryn geal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997; 113: 755—760.

38.Ensrud K.E., Thompson D.E., Cauley J.A., et al. Prevalent ver tebral deformities predict mortality and hospitalization in older women with low bone mass. J. Am. Geriatr. Soc. 2000; 48: 241—249.

39.EUROSCOP (Еuropean study on chronic obstructive pul monary disease).

40.Fagon J.Y., Chastre J., Trouillet J.L., et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: use of protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev. Resp. Dis. 1990; 142: 1004—1008.

41.Gallacher S.J., Fenner J.A., Anderson K., et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease:an open pilot study. Thorax 1992; 47: 932—936.

42.Global strategy for the diagnosis, management and preven tion of chronic obstructive pulmonary disease. National Institute of Health; National Heart, Lung and Blood Institute, updated 2003.

43.Gloth F.M., Gundberg C.M., Hollis B.W., et al. Vitamin D deficien cy in homebound elderly persons. JAMA 1995; 274: 1683—1686.

44.Godschalk M.F., Downs R.W. Effect of short term glucocorti coids on serum osteocalcin in healthy young men. J. Bone Miner. Res. 1988; 3: 113—115.

45.Goldstein M.F., Fallon J.J., Harning R. Chronic glucocorticoid therapy induced osteoporosis in patients with obstructive lung disease. Chest. 1999; 116: 1733—1749.

46.Gompertz S., O’Brien C., Bailay D.L., et al. Change in bronchial inflammaton during acute exacerbation of chronic bronchitis. Eur. Respir. J. 2001; 17: 1112—1119.

47.Harper C.M., Lyles Y.M. Physiology and complications of bed rest. J. Am. Geriat. Soc. 1988; 36: 1047—1054.

48.Hill A.T., Campbell E.J., Hill S.L., et al. Association between airway bacterial load and markers of airway inflammation in

02_Rak_of_old_people_4.qxd 01.12.2005 19:25 Page 212

patients with stable chronic bronchitis. Am. J. Med. 2000; 109: 288—295.

49.Iori E., Dovoli M.L., Dovoli D., et al. La riabilitazione funzionale respiratoria. Giorn. Geront. 1991; 39 (9): 491—496.

50.Iqbal F., Michaelson J., Thaler L., et al. Declining bone mass in men with chronic pulmonary disease. Contribution of glucocr ticoud treatment, body mass index, and gonadal function Chest 1999; 116: 1616—1624.

51.Kado D.M., Browner W.S., Palermo L., et al. Vertebral frac tures and mortality in older women. Arch. Int. Med. 1999; 159: 1215—1220.

52.Katsura H., Kida K. A comparison of bone mineral density in elderly female patients with COPD and bronchial acthma. Chest 2002; 122: 1949—1955.

53.Katz S., Ford A.B., Moskovitz R.W., et al. Studies of ilness in the aged. The index of ADL: a standartized mesure of biological psychosocial function. JAMA 1963; 185: 914—919.

54.Keatings V.M., Collins P.D., Scott D.M., et al. Differences in interleukin 8 and tumr necrosis alpha in induced sputum from patients with chronic obstructive pulmonary disease and asthma. Am J. Respir. Crit. Care Med. 1996; 153: 530—534.

55.Kinzel T. Managing lung disease in late life: A new approach. Geriatrics 1991; 45 (1): 54—59.

56.Lacasse Y., Wong E., Guyott G.H., et al. Lancet. 1996; 348: 1115—1119.

57.Lee T.A., Weiss K.B. Fracture risk associated with inhaled cor ticosteroid use in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169: 855—859.

58.Leech J.A., Dulberg C., Kellie S., et al. Relationship of lung function to severity of osteoporosis in women. Am. Rev. Respir. Dis. 1990; 141: 68—71.

59.Luengo M., del Rio L., Pons F., et al. Bone mineral density in

asthmatic patients treated with inhalated corticosteroids: a case control study. Eur. Resp. J. 1997; 10: 2110—2113.

60.Luengo M., Pons F., Martinez de Osaba M.J., et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year fol low up study. Thorax 1994; 49: 1099—1102.

61.Lukert B.P., Johnson B.E., Robinson R.G. Estrogen and proges terone replacement therapy reduces glucocorticoid induced bone loss. J. Bone Miner. Res. 1992; 7: 1063—1069.

62.Lung Health Study Research Group. Effect of inhaled triamci nolone on the decline in pulmonary function in chronic obstruc tive pulmonary disease. New engl. J. Med. 2000; 343: 1902—1909.

63.Mann G., Hankey G. J., Cameron D. Stroke 1999; 30: 744—748.

64.Masterton R.G., Burley C.J. Randomized, Double Blind Study Comparing 5 and 7 Day Regimens of Oral Levofloxacin in Patients with Acute Exacerbation of Chronic Bronchitis International Journal of Antimicrobial Agents 2001; 18: 503— 513.

02_Rak_of_old_people_4.qxd 01.12.2005 19:25 Page 213

65.McEvoy C.Е., Ensrud K.E., Bender E., et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 704—709.

66.Miravitlles M. Exacerbations of chronic оbstructive pul monary disease when are bacteria important? Eur. Respir. J. 2002; 20 (Suppl. 36): 9—19.

67.Miravitlles M., Guerro T., Mayordomo T., еt al. Factors associ ated with increased risk of exacerbation and hospital admis sion in a cohort of ambulatory COPD patients: a multiple logis tic regression analysis. Respiration 2000; 67: 495—501.

68.Mogukoc N.S., Karakurt B., Isaiska U., et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am. J. Respir. Crit. Care 1999; 160: 349—353.

69.Mokhlesi Babak, Morris Aaron L., Huang, Cheng Fang, et al. Anthony J. Curcio; Terrence A. Barrett, MD and David W. Kamp, MD, FCCP Increased Prevalence of Gastroesophageal Reflux Symptoms in Patients With COPD Chest. 2001; 119: 1043—1048.

70.Monso E., Rossel A., Bonet G., et al. Risk factors for lower air way bacterial colonization in chronic bronchitis. Eur. Respir. J. 1999; 13: 338—342.

71.Monso E., Ruiz J., Rosell A., et al. Bacterial infection in chronic obstructive pulmonary disease. Astudy of stable and exacer bated iutpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 1995; 152: p. 1316, 1320.

72.Niederman M.S. Personal communication. 13th ERS Annual Congress, Vienna, 2003.

73.Ohta K., Fukuchi Y., Grouse L., et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir. Med. 2004; 98: 1016—1024.

74.Openbrier D.R., Irvin M.M., Rogers R.M., et al. Nutritional sta tus and lung function in patients with emphysema and chron ic bronchitis. Chest 1983; 83 (1): 17—22.

75.Orr W.C., Shamma Othman Z., Allen M., et al. Esophageal function and gastroesophageal reflux during sleep and waking in patients with chronic obstructive pulmonary disease. Chest 1992; 101: 1521—1525.

76.Paggiaro L.P. Multicentre randomised placebo controlled trial of inhaled fluticason propionate in patients with COPD. Lancet 1998; 351: 773—780.

77.Рanuccio P. Fisiopatologia respiratoria nell, anziano. Med. Geriatrica 1990; 22: 413—417.

78.Pauwels R.A., Lofdahl C.G., Laitinen L.A., et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948—1953.

79.Pauwels R.A., Lofdahl C.G., Laitinen L.A., et al. Long term treatment with inhaled budesonide in persons with mild

02_Rak_of_old_people_4.qxd 01.12.2005 19:25 Page 214

chronic obstructive pulmonary disease who continue smoking.

N.Engl. J. Med. 1999; 340: 1948—1953.

80.Pechere J.C. Modeling and predicting clinical outcomes of antibiotic therapy. Infect. Med. 1998; 15 (Suppl. E): 46—50.

81.Praet J.P., Peretz A., Rosenberg S., et al. Risk osteoporosis in men with chronic bronchitis. Osteoporos Int. 1992; 2: 257—261.

82.Reid I.R., Wattie D.J., Evans M.C., et al. Testosterone therapy in glucocorticoid treated men. Arch. Intern. Med. 1996; 156: 1173—1177.

83.Riancho J.A., Gonzalez M.J., DelArco C., et al. Vertebral com pression fractures andmineral metabolism in chronic obstruc tive lung disease. Thorax 1987; 42: 962—966.

84.Rossel A., Soler N., Monso E., et al. Differences in microbiolo gical pattern between stable and exacerbated COPD. A pooled analisis of protected specimen brush (PSB) studies. Europ. Resp. J. 2003; 22 (Suppl. 45): 3519A.

85.Saint S., Bent S.,Vitinghoff E., et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta analy sis. JAMA 1995; 273: 957—960.

86.Schols A.M., Wouters E.F. Nutritional abnormalities and sup plementation in chronic obstructive pulmonary disease. Clin. Chest. Med. 2000; 21: 743—762.

87.Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347: 465—471.

88.Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347: 465—471.

89.Sethi S., Muscarella K., Evans N., et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118: 1557—1565.

90.Shane E., Silverberg S.J., Donovan D., et al. Osteoporosis in lung transplantation candidates with end stage pulmonary disease. Am. J. Med. 1996; 101: 262—269.

91.Shea J.E., Miller S.C., Poole D.C., Mattson J.P. Cortical bone dynamics, strength, and densitometry after induction of emphysema in hamsters. J. Appl. Physiol. 2003; 95: 631—634.

92.Shinji Teramoto, MD, FCCP; Haruki Kume, MD and Yasuyochi Ouchi, MD Altered Swallowing Physiology and Aspiration in COPD Chest. 2002; 122: 1104—1105.

93.Slemenda C.W., Hui S.L., Longsope S., et al. Cigarette smoking, obesity, and bone mass. J. Bone Miner. Res. 1989; 4: 737—741.

94.Struys A., Snelder A.A., Mulder H. Cyclical etidronate revers es bone loss of the spine and proximal femur in patients with established corticosteroid induced osteoporosis. Am. J. Med. 1995; 99: 235—242.

95.Susan M. Hardin Oropharyngeal Dysfunction in COPD Patients The Need for Clinical Research. Chest. 2002; 121: 315—317.

96.Svartberg J., Aasebo U., Hjalmarsen A., Sundsfjord J., Jorde

R.Testosterone treatment improves body composition and

02_Rak_of_old_people_4.qxd 01.12.2005 19:25 Page 215

sexual function in men with COPD, in a 6 month randomized controlled trial. Respir Med. 2004 Sep.; 98 (9): 906—913.

97.Van Staa T.P., Leufkens H.G.M., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 2000; 15: 993—1000.

98.Vereen L., Smart L.M., Georg R.B. Antobody cjating and quan titative cultures of bacteria in sputum and bronchial brush spesimens from patients with stable chronic bronchitis. Chest 1986; 90: 534—536.

99.Wang W.Q., Man M.S., Tsang Q.W.T., et al. Antiresorptive therapy in asthmatic patients receiving high dose inhaled steroids: a prospective study for 18 months. J. Allergy. Clin. Immunol. 1998; 101: 445—450.

100.Ware J.E. The SF 36 Health Survey Manual Interpretation Guide. Boston Nimrod Press 1993.

101.Wilson R., Allegra L., Huchon G., et al. Short and long outcomes of moxifloxacin (MXF) compared to standard antibiotic treat ment (STD) in acute exacerbations of chronic bronchitis (AECB). The MOSAIC study. Eur. Resp. J. 2003; 22 (Suppl. 45): 3559A.

102.Wise R., Connet J., Weinmann G., et al. Effect of inhaled tri amcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902—1909.

103.Wong C.A., Walsh L.J., Smith C.J., et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 2000; 355: 1399—1403.

104.Yeh S., DeGuzman B., Kramer T. Reversal of COPD Associated Weight Loss Using the Anabolic Agent Oxandrolone Chest. 2002; 122: 421—428.

105.Zalacain R., Sobradillo V., Amilibia J., et al. Predisposing fac tors to bacterial colonization in chronic obstructive pulmonary disease. Eur. Respir. J. 1999; 13: 343—348.

106.Zbranca V., Mocanu V., Descalescu I., et al. Body composition and osteoporosis in COPD patients. Eur. Resp. J. 2003; 22 (Suppl. 45): 538 s.

02_Rak_of_old_people_4.qxd 01.12.2005 19:25 Page 216

Издательство «Литтерра» (ГK «Бионика»)

Председатель Правления ГK «Бионика» — Ю. А. Крестинский Генеральный директор издательства «Литтерра» — В. А. Мефодовский

Справочное издание

Библиотека пульмонолога

Серия «Опыт клинической практики»

Л. И. Дворецкий

Ведение пожилого больного ХОБЛ

Редакторы — В. В. Кулеш, В. Г. Круглик

Выпускающий редактор — Л. А. Агадулина

Корректор — Е. А. Остроумова

Макет, компьютерная верстка — Е. В. Беридзе Менеджер по полиграфии — А. Г. Игошин

Сдано в набор 01.08.05. Подписано в печать 30.11.05. Бумага офсетная. Формат 84х108/32.

Гарнитура «JournalC». Печать офсетная. Усл. печ. л. 11,34.

Тираж 5000 экз. Заказ №

ЗАО «Издательство «Литтерра». 117420 г. Москва, ул. Профсоюзная, д. 57 http://www.litterra.ru; e mail: info@litterra.ru

Отпечатано в полном соответствии с оригинал макетом в ООО «Чебоксарская типография № 1», 428019 г. Чебоксары, пр. И. Яковлева, д. 15